NDAORALTABLET
Approved
Nov 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBUNOX is a fixed-dose combination oral tablet containing ibuprofen (a nonsteroidal anti-inflammatory drug) and oxycodone hydrochloride (an opioid analgesic). It was developed to provide enhanced analgesia for moderate to severe acute pain by combining anti-inflammatory and opioid mechanisms. The product targets patients requiring multimodal pain management beyond monotherapy.
LOE Approaching
With LOE approaching, the brand team is likely transitioning to lifecycle extension or wind-down strategies, suggesting reduced headcount and focus on generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on COMBUNOX offers limited career growth given the LOE timeline and declining market trajectory. Professionals should expect smaller teams, defensive strategies, and opportunities to learn lifecycle management and generic transition planning rather than growth-phase marketing.
Brand ManagerSenior Sales Representative
Worked on COMBUNOX at Forest Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.